Ramky Infrastructure executes sale of Visakha Pharmacity stake for INR 165.24 Crores
M&A
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 31 Mar 2026, 09:17 PM IST · BSE ID: 8ec02ed6-e1ba-4c77-a0ed-80ec6c6849dc
View Original BSE Filing (PDF)
💡
In Simple Terms
Ramky Infrastructure sold its entire stake in Visakha Pharmacity to a construction company for INR 165.24 Crores, completing a Board-approved divestment.
🤖 AI Summary
- Executed Share Purchase Agreement on 30.03.2026 for sale of 51% stake in Visakha Pharmacity Limited
- Consideration received: INR 165.24 Crores from Brij Gopal Construction Company Private Limited
- Share transfers expected within 10 days from SPA execution — completion timeline set
- VPCL contributed INR 4,093.29 million consolidated turnover and INR 3,023.26 million net worth in FY24-25
- Not a related party transaction — buyer does not belong to promoter group
🔢 Key Numbers — exact figures from BSE filing, not rounded
Sale consideration received
INR 165.24 Crores
Stake divested
51% (91,80,000 equity shares of Visakha Pharmacity Limited)
VPCL consolidated turnover FY24-25
INR 4,093.29 million
VPCL consolidated net worth FY24-25
INR 3,023.26 million
SPA execution date
30.03.2026
Expected completion timeline
Within 10 days from SPA execution
🏢 How This Affects the Company
Divestment removes Visakha Pharmacity — which contributed INR 4,093.29 million consolidated turnover in FY24-25 — from RIL's operational portfolio. Future revenue will exclude this subsidiary's earnings.
RIL receives INR 165.24 Crores cash consideration upfront. Net worth impact depends on the sale price relative to VPCL's carrying book value of INR 3,023.26 million consolidated net worth. Gain or loss on divestment will flow to P&L in the quarter of completion.
RIL ceases operational control over Visakha Pharmacity. The subsidiary will no longer be consolidated in RIL's financial statements post-completion.
Divestment reduces RIL's diversification in the pharmaceutical real estate sector. Buyers does not belong to promoter group — arm's length transaction reduces conflict of interest risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required. Monitor FY25-26 quarterly results for impact of VPCL deconsolidation on reported revenue and earnings.
👤
Who Is Affected
All RIL shareholders. The divestment reduces consolidated turnover by INR 4,093.29 million annually. Shareholders will see a lower consolidated revenue base from Q1 FY26 onward once the transaction closes.
🔍
Management Signal
Strategic decision to exit pharmaceutical real estate subsidiary and unlock INR 165.24 Crores cash. Signals focus on core infrastructure business and capital reallocation.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Transaction completion filing — watch BSE for Reg 31A(10) disclosure confirming share transfer closure
FY25-26 Q1 results — verify consolidated revenue excluding VPCL contribution from INR 4,093.29 million
Auditor's report on gain/loss on divestment — check accounting impact on FY25-26 net profit
MEDIUM RISK
Loss of INR 4,093.29 million annual consolidated turnover. Gain/loss on divestment not quantified — could be material to earnings.
💡 Investor Takeaway
RIL has executed sale of 51% stake in Visakha Pharmacity for INR 165.24 Crores cash, received upfront. VPCL contributed INR 4,093.29 million consolidated turnover in FY24-25 — this revenue exits the consolidated base upon completion within 10 days.
⚖️ Strengths & Concerns
✅ Positives
- Consideration of INR 165.24 Crores received upfront — no deferred payment risk to balance sheet
- Transaction completed at arm's length to non-promoter buyer — clean governance and no related party concerns
⚠️ Concerns
- Loss of INR 4,093.29 million consolidated annual turnover from VPCL post-divestment reduces revenue base
- Sale price relative to net worth of INR 3,023.26 million not disclosed — gain/loss magnitude unclear from filing
📅 Company Track Record
Board approved the sale on 28.03.2026. SPA executed on 30.03.2026. Visakha Pharmacity was a 51%-held subsidiary contributing material revenue (INR 4,093.29 million) and net worth (INR 3,023.26 million) to consolidated financials in FY24-25.
Based on publicly available historical data. For context only.